ATE209045T1 - Hepatitis b impfstoff - Google Patents

Hepatitis b impfstoff

Info

Publication number: ATE209045T1
Authority: AT; Austria
Prior art keywords: vaccine; hepatitis
Prior art date: 1995-02-25

Application number

AT96904814T

Other languages

English (en)

Inventor

Pierre Hauser

Nathalie Marie-Josephe Garcon

Pierre Desmons

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-25

Filing date

1996-02-15

Publication date

2001-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10770292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE209045(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-02-15 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

2001-12-15 Application granted granted Critical

2001-12-15 Publication of ATE209045T1 publication Critical patent/ATE209045T1/de

Links

SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 title 1
229940124736 hepatitis-B vaccine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT96904814T 1995-02-25 1996-02-15 Hepatitis b impfstoff ATE209045T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9503863.4A GB9503863D0 (en)	1995-02-25	1995-02-25	Vaccine compositions
PCT/EP1996/000681 WO1996026741A1 (en)	1995-02-25	1996-02-15	Hepatitis b vaccine

Publications (1)

Publication Number	Publication Date
ATE209045T1 true ATE209045T1 (de)	2001-12-15

Family

ID=10770292

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96904814T ATE209045T1 (de)	1995-02-25	1996-02-15	Hepatitis b impfstoff

Country Status (35)

Country	Link
US (1)	US5972346A (de)
EP (1)	EP0810877B1 (de)
JP (1)	JP3881015B2 (de)
KR (1)	KR100365373B1 (de)
CN (1)	CN1101225C (de)
AP (1)	AP766A (de)
AR (1)	AR002279A1 (de)
AT (1)	ATE209045T1 (de)
AU (1)	AU695921B2 (de)
BG (1)	BG101851A (de)
BR (1)	BR9607458A (de)
CA (1)	CA2212552C (de)
CZ (1)	CZ288417B6 (de)
DE (1)	DE69617211T2 (de)
DK (1)	DK0810877T3 (de)
EA (1)	EA199700126A1 (de)
ES (1)	ES2166879T3 (de)
FI (1)	FI118118B (de)
GB (1)	GB9503863D0 (de)
HU (1)	HU224832B1 (de)
IL (1)	IL117249A (de)
MA (1)	MA23814A1 (de)
MX (1)	MX9706450A (de)
MY (1)	MY113428A (de)
NO (1)	NO319394B1 (de)
NZ (1)	NZ302674A (de)
OA (1)	OA10612A (de)
PL (1)	PL182679B1 (de)
PT (1)	PT810877E (de)
SA (1)	SA96160633B1 (de)
SK (1)	SK115097A3 (de)
TR (1)	TR199700849T1 (de)
TW (1)	TW467745B (de)
WO (1)	WO1996026741A1 (de)
ZA (1)	ZA961460B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6620414B2 (en) *	1992-03-27	2003-09-16	Smithkline Beecham Biologicals (S.A.)	Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
FR2711670B1 (fr)	1993-10-22	1996-01-12	Pasteur Institut	Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6488934B1 (en) *	1995-02-25	2002-12-03	Smithkline Beecham Biologicals S.A.	Hepatitis B vaccine
US20010014331A1 (en) *	1996-11-07	2001-08-16	Smithkline Beecham Biologicals S.A.	Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9809507D0 (en) *	1998-05-01	1998-07-01	Smithkline Beecham Biolog	Novel composition
US20030049268A1 (en)	1998-05-01	2003-03-13	Smithkline Beecham Biologicals S.A.	Novel composition
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6306404B1 (en)	1998-07-14	2001-10-23	American Cyanamid Company	Adjuvant and vaccine compositions containing monophosphoryl lipid A
ES2284287T3 (es)	1998-10-16	2007-11-01	Glaxosmithkline Biologicals S.A.	Sistemas adyuvantes y vacunas.
CU22871A1 (es) *	1998-12-02	2003-10-21	Ct Ingenieria Genetica Biotech	Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CA2355680A1 (en) *	1998-12-23	2000-06-29	Qinjian Zhao	Improved recombinant hepatitis b surface antigen
DK1187629T3 (da)	1999-04-19	2005-01-17	Glaxosmithkline Biolog Sa	Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6635261B2 (en)	1999-07-13	2003-10-21	Wyeth Holdings Corporation	Adjuvant and vaccine compositions containing monophosphoryl lipid A
CU23031A1 (es) *	2002-01-24	2005-02-23	Ct Ingenieria Genetica Biotech	Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
AU2006215419B2 (en) *	2005-02-16	2012-03-08	Novartis Vaccines And Diagnostics, Inc.	Adjuvant composition comprising aluminium phosphate and 3D-MPL
BRPI0614254A2 (pt) *	2005-08-02	2011-03-15	Novartis Vaccines & Diagnostic	redução de interferência entre adjuvantes contendo óleo e antìgenos contendo tensoativos
WO2007052055A1 (en)	2005-11-04	2007-05-10	Novartis Vaccines And Diagnostics Srl	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628424A1 (en)	2005-11-04	2007-05-10	Novartis Vaccines And Diagnostics S.R.L.	Adjuvanted influenza vaccines including cytokine-inducing agents
ES2377884T3 (es)	2005-11-04	2012-04-02	Novartis Vaccines And Diagnostics S.R.L.	Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
NZ594482A (en)	2005-11-04	2012-11-30	Novartis Vaccines & Diagnostic	Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CN100415294C (zh) *	2005-12-23	2008-09-03	中国农业大学	一种治疗和/或预防乙肝的药物
PL2478916T3 (pl)	2006-01-27	2020-11-16	Seqirus UK Limited	Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
ATE539079T1 (de)	2006-03-23	2012-01-15	Novartis Ag	Imidazochinoxalinverbindungen als immunmodulatoren
WO2007110776A1 (en)	2006-03-24	2007-10-04	Novartis Vaccines And Diagnostics Gmbh & Co Kg	Storage of influenza vaccines without refrigeration
EP1862176A1 (de) *	2006-05-31	2007-12-05	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) *	2006-06-01	2007-12-05	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Ein Verfahren zur Herstellung einer Impfzusammensetzung
DK2054431T3 (da)	2006-06-09	2012-01-02	Novartis Ag	Konformere af bakterielle adhæsiner
GB0614460D0 (en)	2006-07-20	2006-08-30	Novartis Ag	Vaccines
NZ575271A (en)	2006-09-11	2011-09-30	Novartis Ag	Making influenza virus vaccines without using eggs
JP2011506264A (ja)	2006-12-06	2011-03-03	ノバルティスアーゲー	インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
PT2185191E (pt)	2007-06-27	2012-11-27	Novartis Ag	Vacinas contra a gripe com baixo teor de aditivos
GB0810305D0 (en)	2008-06-05	2008-07-09	Novartis Ag	Influenza vaccination
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2235532B1 (de)	2007-12-24	2013-04-24	Novartis AG	Testverfahren für adsorbierte grippeimpfstoffe
EP4183412B1 (de)	2009-07-15	2024-08-14	GlaxoSmithKline Biologicals SA	Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
ES3018416T3 (es)	2011-01-26	2025-05-16	Glaxosmithkline Biologicals Sa	Régimen de inmunización del VRS
US9452212B2 (en)	2011-04-14	2016-09-27	Dynavax Technologies Corporation	Methods and compositions for eliciting an immune response against hepatitis B virus
RS56748B1 (sr)	2011-05-13	2018-03-30	Glaxosmithkline Biologicals Sa	Pre-fuzioni rsv f antigeni
KR20180035807A (ko)	2015-06-26	2018-04-06	세퀴러스 유케이 리미티드	항원적으로 매치된 인플루엔자 백신
WO2020099927A1 (en)	2018-11-13	2020-05-22	Variation Biotechnologies Inc.	Immunogenic compositions for treatment of hepatitis b

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
DK0414374T3 (da) *	1989-07-25	1998-03-09	Smithkline Beecham Biolog	Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
CA2109714A1 (en) *	1991-05-29	1992-12-10	Frederic H. Moll	Retraction apparatus and methods for endoscopic surgery
MY111880A (en) *	1992-03-27	2001-02-28	Smithkline Beecham Biologicals S A	Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
JP3626996B2 (ja) *	1992-05-23	2005-03-09	グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム	Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
KR100310510B1 (ko) *	1993-03-23	2002-07-04	장 스테판느	3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9311536D0 (en) *	1993-06-04	1993-07-21	Unilever Plc	Hot soluble low density extractable food product

1995
- 1995-02-25 GB GBGB9503863.4A patent/GB9503863D0/en active Pending
1996
- 1996-02-14 MY MYPI96000567A patent/MY113428A/en unknown
- 1996-02-15 SK SK1150-97A patent/SK115097A3/sk unknown
- 1996-02-15 DE DE69617211T patent/DE69617211T2/de not_active Expired - Lifetime
- 1996-02-15 JP JP52598896A patent/JP3881015B2/ja not_active Expired - Fee Related
- 1996-02-15 PL PL96321966A patent/PL182679B1/pl unknown
- 1996-02-15 DK DK96904814T patent/DK0810877T3/da active
- 1996-02-15 AT AT96904814T patent/ATE209045T1/de active
- 1996-02-15 CA CA002212552A patent/CA2212552C/en not_active Expired - Fee Related
- 1996-02-15 HU HU9801242A patent/HU224832B1/hu not_active IP Right Cessation
- 1996-02-15 PT PT96904814T patent/PT810877E/pt unknown
- 1996-02-15 NZ NZ302674A patent/NZ302674A/xx not_active IP Right Cessation
- 1996-02-15 WO PCT/EP1996/000681 patent/WO1996026741A1/en not_active Ceased
- 1996-02-15 EP EP96904814A patent/EP0810877B1/de not_active Expired - Lifetime
- 1996-02-15 EA EA199700126A patent/EA199700126A1/ru unknown
- 1996-02-15 CZ CZ19972674A patent/CZ288417B6/cs not_active IP Right Cessation
- 1996-02-15 AP APAP/P/1997/001060A patent/AP766A/en active
- 1996-02-15 KR KR1019970705880A patent/KR100365373B1/ko not_active Expired - Fee Related
- 1996-02-15 US US08/894,643 patent/US5972346A/en not_active Expired - Lifetime
- 1996-02-15 BR BR9607458A patent/BR9607458A/pt not_active IP Right Cessation
- 1996-02-15 AU AU48780/96A patent/AU695921B2/en not_active Ceased
- 1996-02-15 ES ES96904814T patent/ES2166879T3/es not_active Expired - Lifetime
- 1996-02-15 TR TR97/00849T patent/TR199700849T1/xx unknown
- 1996-02-15 CN CN96192146A patent/CN1101225C/zh not_active Expired - Fee Related
- 1996-02-22 AR ARP960101469A patent/AR002279A1/es active IP Right Grant
- 1996-02-23 MA MA24171A patent/MA23814A1/fr unknown
- 1996-02-23 IL IL11724996A patent/IL117249A/xx not_active IP Right Cessation
- 1996-02-23 ZA ZA961460A patent/ZA961460B/xx unknown
- 1996-02-26 TW TW085102154A patent/TW467745B/zh not_active IP Right Cessation
- 1996-03-02 SA SA96160633A patent/SA96160633B1/ar unknown
1997
- 1997-08-02 OA OA70066A patent/OA10612A/en unknown
- 1997-08-22 FI FI973457A patent/FI118118B/fi not_active IP Right Cessation
- 1997-08-22 NO NO19973873A patent/NO319394B1/no not_active IP Right Cessation
- 1997-08-22 MX MX9706450A patent/MX9706450A/es unknown
- 1997-08-25 BG BG101851A patent/BG101851A/xx unknown

Also Published As

Publication number	Publication date
IL117249A (en)	2000-11-21
SA96160633B1 (ar)	2005-10-15
PL321966A1 (en)	1998-01-05
DK0810877T3 (da)	2002-02-25
HK1004117A1 (en)	1998-11-20
MY113428A (en)	2002-02-28
CZ267497A3 (cs)	1998-02-18
NZ302674A (en)	1999-01-28
DE69617211D1 (en)	2002-01-03
CZ288417B6 (en)	2001-06-13
TW467745B (en)	2001-12-11
OA10612A (en)	2002-08-29
PL182679B1 (pl)	2002-02-28
DE69617211T2 (de)	2002-07-25
JPH11501018A (ja)	1999-01-26
IL117249A0 (en)	1996-06-18
HU224832B1 (en)	2006-03-28
BG101851A (en)	1998-04-30
FI973457A0 (fi)	1997-08-22
GB9503863D0 (en)	1995-04-19
SK115097A3 (en)	1998-02-04
ZA961460B (en)	1996-08-29
CN1101225C (zh)	2003-02-12
AP9701060A0 (en)	1997-10-31
FI973457L (fi)	1997-08-22
NO319394B1 (no)	2005-08-08
BR9607458A (pt)	1998-06-30
AR002279A1 (es)	1998-03-11
EP0810877B1 (de)	2001-11-21
HUP9801242A3 (en)	2000-08-28
MA23814A1 (fr)	1996-10-01
US5972346A (en)	1999-10-26
TR199700849T1 (xx)	1998-01-21
CN1176604A (zh)	1998-03-18
EA199700126A1 (ru)	1998-02-26
PT810877E (pt)	2002-04-29
EP0810877A1 (de)	1997-12-10
KR100365373B1 (ko)	2003-07-07
AP766A (en)	1999-09-17
WO1996026741A1 (en)	1996-09-06
CA2212552A1 (en)	1996-09-06
MX9706450A (es)	1998-07-31
NO973873L (no)	1997-08-22
HUP9801242A1 (hu)	1998-08-28
AU695921B2 (en)	1998-08-27
ES2166879T3 (es)	2002-05-01
AU4878096A (en)	1996-09-18
JP3881015B2 (ja)	2007-02-14
NO973873D0 (no)	1997-08-22
FI118118B (fi)	2007-07-13
CA2212552C (en)	2006-07-11
KR19980702480A (ko)	1998-07-15

Legal Events

Date	Code	Title	Description
2002-05-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
DK0810877T3 (da)	2002-02-25	Hepatitis B-vaccine
NO976060D0 (no)	1997-12-23	Vaksiner mot hepatitt C
NO20003303L (no)	2000-08-04	Vaksine
KR970704468A (ko)	1997-09-06	폴리에피토프 백신(polyepitope vaccines)
BR9711853A (pt)	1999-08-24	Vacinas
FI964592L (fi)	1996-11-15	Papilloomavirusrokotteita
ID20399A (id)	1998-12-10	Vaksin influensa
DE69126606D1 (de)	1997-07-24	Vakzine
DK0736303T3 (da)	2000-01-10	Interferonopløsning
FI944052A7 (fi)	1994-09-02	Oraalinen rokote
EP0967993A4 (de)	2001-04-18	Anti-kokaine vakzine
ATE253641T1 (de)	2003-11-15	Antigenische präparationen
DE69509766D1 (de)	1999-06-24	Mikroemulsionen
DE69628167D1 (de)	2003-06-18	Spezifische oligonukleotide fuer hepatitis c-virus
IT1276662B1 (it)	1997-11-03	Vaccini polinucleotidici
FI973755A7 (fi)	1997-10-14	Viistokantaniitti
NO933600D0 (no)	1993-10-08	Termostabile virus
ITMI950511A0 (it)	1995-03-16	Fotodensitometro parallelo perfezionato
NO980721D0 (no)	1998-02-20	Vaksiner
SI0810877T1 (en)	2002-06-30	Hepatitis b vaccine
DE69326536D1 (de)	1999-10-28	Antitumor Impfstoff
FI944558A0 (fi)	1994-09-30	Virus
UA24703A (uk)	1998-10-30	Емітерний повторювач
BR7502544U (pt)	1998-05-05	Easy baby
KR970703417A (ko)	1997-07-03	유두종 바이러스 백신(Papillomavirus vaccines)